Highlights from the Week of 19th October 2026 - 26th October 2026

VYUHPHARMA

(FDA , Approval)

FDA approves GSK's JEMPERLI for adults with stage II and III MSI-H or dMMR locally advanced rectal cancer

(FDA , Approval)

GSK's HIBSAGO receives FDA approval for the treatment of CHB in combination with Nrtl therapy in adults without cirrhosis

(FDA , Approval)

FDA gives approval to AbbVie's SKYRIZI SC induction regimen for adults with moderately to severely active CD

(EC, Approval)

Novartis receives EC approval for COSENTYX indicated to treat adults with PMR with inadequate response to glucocorticoids or relapse during taper

All logos and trademarks remain the intellectual properties of their respective owners

(EC, Approval)

EC provides approval to Merck's KEYTRUDA in combination with PADCEV as neoadjuvant and as adjuvant treatments for adults with resectable MIBC

(Health Canada, Approval)

Health Canada approves AbbVie's SKYRIZI for the treatment of those aged 6 to <18 years with moderate to severe plaque psoriasis

(NMPA, Approval)

NMPA approves Galderma's RELFYDESS for the temporary improvement of moderate-to-severe frown lines in adults

(NMPA, Approval)

Harbour BioMed gets NMPA approval for its BLA for batoclimab SC, 1 mL/vial for the treatment of gMG in adults who are AChR antibody positive

All logos and trademarks remain the intellectual properties of their respective owners

VYUHPHARMA

(FDA, Accelerated Approval)

AstraZeneca obtains FDA accelerated approval for ULTOMIRIS indicated for proteinuria reduction in IgAN

(FDA, Fast Track)

Samsung Bioepis' SBE303 gets FDA Fast Track designation for locally advanced or metastatic urothelial cancer who received enfortumab vedotin

(Acquisition)

Ambrose Healthcare acquires AM-Pharma, along with its Ph2 HPP treatment-ready candidate, for up to €161M, expanding its rare disease pipeline

(Collaboration)

AI Proteins collaborate with Astellas Innovation Management LLC to discover and develop novel miniprotein-based therapeutics for an upfront payment of $400M

All logos and trademarks remain the intellectual properties of their respective owners

VYUHPHARMA

(Collaboration)

Menarini Group collaborates with Stemline Therapeutics for GIM-621, indicated for the treatment across multiple solid tumors, receiving an upfront payment of $45M

(Collaboration)

Kaigene collaborates with Celltrion to develop and commercialize KG013, receiving a total payment up to $580.5M

(Phase 3, Results)

AbbVie's Ph3 INTREPID study evaluating lutikizumab in adults and adolescents with moderate to severe HS met its primary and 8 ranked secondary endpoints, with no increase in abscess and draining fistula counts relative to baseline

(Phase 3, Results)

Takeda's Ph3 G-HOPE-001 study evaluating TAK-921 in CLDN 18.2-positive, previously treated, advanced G/GEJA met its dual primary endpoints of OS and PFS

All logos and trademarks remain the intellectual properties of their respective owners